These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8505491)

  • 1. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy.
    Adams PC; Kertesz AE; Valberg LS
    J Clin Gastroenterol; 1993 Apr; 16(3):207-10. PubMed ID: 8505491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting the rate of iron mobilization during venesection therapy for genetic hemochromatosis.
    Adams PC
    Am J Hematol; 1998 May; 58(1):16-9. PubMed ID: 9590143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of serum ferritin in the management of idiopathic haemochromatosis.
    Batey RG; Hussein S; Sherlock S; Hoffbrand AV
    Scand J Gastroenterol; 1978; 13(8):953-7. PubMed ID: 725519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idiopathic hemochromatosis: serum ferritin concentrations during therapy by phlebotomy.
    Garry PJ; Saiki JH
    Clin Chem; 1982 Aug; 28(8):1806-8. PubMed ID: 7094303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and management of hereditary hemochromatosis.
    Valberg LS; Ghent CN
    Annu Rev Med; 1985; 36():27-37. PubMed ID: 3888053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low serum 25-hydroxyvitamin D in hereditary hemochromatosis: relation to iron status.
    Chow LH; Frei JV; Hodsman AB; Valberg LS
    Gastroenterology; 1985 Apr; 88(4):865-9. PubMed ID: 3838288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic venesection at the Australian Red Cross Blood Service: impact of the High Ferritin Application on management of hereditary haemochromatosis.
    Bentley P; Bell B; Olynyk J
    Aust Fam Physician; 2015 Aug; 44(8):589-92. PubMed ID: 26510149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of therapeutic erythrocytapheresis to achieve iron depletion in hereditary type 1 hemochromatosis: report of 30 cases].
    Poullin P; Lefèvre PA
    Transfus Clin Biol; 2011 Dec; 18(5-6):553-8. PubMed ID: 22019606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum ferritin in haemochromatosis: changes in the isoferritin composition during venesection therapy.
    Halliday JW; McKeering LV; Tweedale R; Powell LW
    Br J Haematol; 1977 Jul; 36(3):395-404. PubMed ID: 19030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring of intensive phlebotomy therapy in iron overload by serum ferritin assay.
    van Oost BA; van den Beld B; van Asbeck BS; Marx JJ
    Am J Hematol; 1985 Jan; 18(1):7-12. PubMed ID: 3966464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term results of venesection therapy in idiopathic haemochromatosis.
    Bomford A; Williams R
    Q J Med; 1976 Oct; 45(180):611-23. PubMed ID: 188063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of body iron stores to levels of serum ferritin, serum iron, unsaturated iron binding capacity and transferrin saturation in patients with iron storage disease.
    Beutler E; Felitti V; Ho NJ; Gelbart T
    Acta Haematol; 2002; 107(3):145-9. PubMed ID: 11978935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of food iron absorption on the plasma iron level in idiopathic hemochromatosis.
    Milder MS; Cook JD; Finch CA
    Acta Haematol; 1978; 60(2):65-75. PubMed ID: 98952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemochromatosis: evaluating the effectiveness of a novel patient self-management approach to venesection as blood donation.
    Mishra S; Sim D; Flanagan P
    N Z Med J; 2017 Jun; 130(1457):26-33. PubMed ID: 28617785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nontransferrin-bound iron in plasma from hemochromatosis patients: effect of phlebotomy therapy.
    Aruoma OI; Bomford A; Polson RJ; Halliwell B
    Blood; 1988 Oct; 72(4):1416-9. PubMed ID: 2458783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests.
    Bassett ML; Halliday JW; Ferris RA; Powell LW
    Gastroenterology; 1984 Sep; 87(3):628-33. PubMed ID: 6745616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotypic/phenotypic correlations in genetic hemochromatosis: evolution of diagnostic criteria.
    Adams PC; Chakrabarti S
    Gastroenterology; 1998 Feb; 114(2):319-23. PubMed ID: 9453492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of hemochromatosis. Hemochromatosis Management Working Group.
    Barton JC; McDonnell SM; Adams PC; Brissot P; Powell LW; Edwards CQ; Cook JD; Kowdley KV
    Ann Intern Med; 1998 Dec; 129(11):932-9. PubMed ID: 9867745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload (Mi-Iron): a multicentre, participant-blinded, randomised controlled trial.
    Ong SY; Gurrin LC; Dolling L; Dixon J; Nicoll AJ; Wolthuizen M; Wood EM; Anderson GJ; Ramm GA; Allen KJ; Olynyk JK; Crawford D; Ramm LE; Gow P; Durrant S; Powell LW; Delatycki MB
    Lancet Haematol; 2017 Dec; 4(12):e607-e614. PubMed ID: 29195602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial serum ferritin measurements in untreated HFE C282Y homozygotes in the Hemochromatosis and Iron Overload Screening Study.
    Adams PC; Reboussin DM; Barton JC; Acton RT; Speechley M; Leiendecker-Foster C; Meenan R; Passmore L; McLaren CE; McLaren GD; Gordeuk V; Dawkins F; Eckfeldt JH
    Int J Lab Hematol; 2008 Aug; 30(4):300-5. PubMed ID: 18665827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.